Therapeutic progress--review XVIII Alzheimer's disease.
Kendall
M J
MJ
Chellingsworth
M C
MC
Main
A N
AN
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000628:therapy; D002560:Cerebrovascular Circulation / Q000187:drug effects; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D006801:Humans; D009257:Nafronyl / Q000627:therapeutic use; D009270:Naloxone / Q000627:therapeutic use; D018377:Neurotransmitter Agents / Q000502:physiology; D010277:Parasympathomimetics / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D010889:Piracetam / Q000627:therapeutic use; D011613:Psychotherapy; D014665:Vasodilator Agents / Q000627:therapeutic use
D002800:Cholinesterase Inhibitors; D018377:Neurotransmitter Agents; D010277:Parasympathomimetics; D010455:Peptides; D014665:Vasodilator Agents; D009270:Naloxone; D009257:Nafronyl; D010889:Piracetam